PuSH - Publication Server of Helmholtz Zentrum München

32 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Clemmensen, C. et al.: Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. Nat. Rev. Endocrinol. 15, 90-104 (2019)
2.
Décarie-Spain, L.* et al.: GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice. Neuropharmacol. 151, 55-63 (2019)
3.
Khajavi, N.* et al.: Tri-agonist-induced PLC activation is associated with robust insulin secretion from murine islets. Naunyn-Schmiedebergs Arch. Pharmakol. 392, S35-S35 (2019)
4.
Mroz, P.A.* et al.: Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mol. Metab. 20, 51-62 (2019)
5.
Ratner, C.* et al.: Long-acting neurotensin synergizes with liraglutide to reverse obesity through a melanocortin-dependent pathway. Diabetes 68, 1329-1340 (2019)
6.
Brandt, S. ; Mayer, J.P.* ; Ford, J.* ; Gelfanov, V.M.* & DiMarchi, R.D.*: Controlled intramolecular antagonism as a regulator of insulin receptor maximal activity. Peptides 100, 18-23 (2018)
7.
Brandt, S. ; Müller, T.D. ; DiMarchi, R.D.* ; Tschöp, M.H. & Stemmer, K.: Peptide-based multi-agonists: A new paradigm in metabolic pharmacology. J. Intern. Med. 284, 581-602 (2018)
8.
Capozzi, M.E.* ; DiMarchi, R.D.* ; Tschöp, M.H. ; Finan, B.* & Campbell, J.E.*: Targeting the incretin/glucagon system with triagonists to treat diabetes. Endocr. Rev. 39, 719-738 (2018)
9.
DiMarchi, R.D.* ; Mayer, J.P.* ; Gelfanov, V.M.* & Tschöp, M.H.: Max Bergmann award lecture: Macromolecular medicinal chemistry as applied to metabolic diseases. J. Pept. Sci. 24:e3056 (2018)
10.
Khajavi, N.* et al.: An incretin-based tri-agonist promotes superior insulin secretion from murine pancreatic islets via PLC activation. Cell. Signal. 51, 13-22 (2018)
11.
Müller, T.D. ; Clemmensen, C. ; Finan, B. ; DiMarchi, R.D.* & Tschöp, M.H.: Anti-obesity therapy: From rainbow pills to polyagonists. Pharmacol. Rev. 70, 712-746 (2018)
12.
Frias, J.P.* et al.: The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab. 26, 343-352.e2 (2017)
13.
Jall, S. et al.: Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Mol. Metab. 6, 440-446 (2017)
14.
Kleinert, M. et al.: Emerging poly-agonists for obesity and type 2 diabetes. Obesity 25, 1647-1649 (2017)
15.
Knerr, P.J.* et al.: Optimization of peptide-based polyagonists for treatment of diabetes and obesity. Bioorg. Med. Chem. 26, 2873-2881 (2017)
16.
Mayer, J.P.* ; Tschöp, M.H. & DiMarchi, R.D.*: Once blind, now we see GLP-1 molecular action. Cell Metab. 26, 289-291 (2017)
17.
Müller, T.D. ; Finan, B. ; Clemmensen, C. ; DiMarchi, R.D. & Tschöp, M.H.: The new biology and pharmacology of glucagon. Physiol. Rev. 97, 721-766 (2017)
18.
Quarta, C. et al.: Molecular integration of incretin and glucocorticoid action reverses immunometabolic dysfunction and obesity. Cell Metab. 26, 620-632.e6 (2017)
19.
Sánchez-Garrido, M.A. et al.: GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia 60, 1851–1861 (2017)
20.
Sánchez-Garrido, M.A. et al.: Fibroblast activation protein (FAP) as a novel metabolic target. Mol. Metab. 5, 1015-24 (2016)